Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Udo Oppermann

Professor of Molecular Biology

  • Director of Molecular Laboratory Sciences, Botnar Research Centre
  • Deputy Director Oxford Centre of Translational Myeloma Research

Professor Udo Oppermann obtained his Diploma in Human Biology in 1990 and his PhD in Pharmacology and Toxicology in 1994, both with distinctions from Philipps University Marburg, Germany.
He went on to become Associate Professor at Karolinska Institutet, Stockholm, in the Department of Medical Biochemistry and Biophysics where he stayed until 2004.
After a sabbatical stay at Yale University, he has been a Principal Investigator of the Structural Genomics Consortium (SGC) in Oxford since its inception in 2003.
In 2008 he became Professor of Molecular Biology at NDORMS, and he is now Director of the Laboratory Sciences Division at the Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford. He is a fellow of St Catherine's College at Oxford University as well as an alumnus of the Freiburg Institute of Advanced Studies through a Senior Marie Curie fellowship.
The research in the Oppermann group focuses on drug and target discovery by using systems biology and single-cell approaches in a variety of human diseases including metabolic, inflammatory and malignant diseases. Application of novel single-cell technologies and chemical biology in primary and secondary bone cancers such as multiple myeloma with a focus on epigenetic mechanisms is a key research area of the group.


  • Cancer Research UK 
  • Innovate UK 
  • EPSRC 
  • Royal Society- Newton Fund 
  • Bristol Myers Squibb 
  • Bayer Healthcare 
  • GlaxoSmithKline 
  • Blood Cancer UK 
  • Leducq Foundation

Key publications

Recent publications

More publications